Search

everythinglearnresearchcommunity

for

Search:↓

Increased regulatory T cell activity may lead to better outcomes in acute diffuse and total alopecia.

Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.

Baricitinib is a relatively safe and effective treatment for severe alopecia areata.

Baricitinib is more effective than methotrexate for severe alopecia areata.

Edar and Eda proteins are crucial for proper tooth development.

Depression and hair loss may influence each other.

Tofacitinib can be effective in treating hair loss caused by alopecia areata.

JAK inhibitors are effective and safe for treating severe alopecia areata.

Tofacitinib may be an effective and safe treatment for hair loss in teenagers with alopecia areata.

Baricitinib helps keep hair, eyebrows, and eyelashes regrown for 3 years in most people with severe hair loss.

Tofacitinib may be safe and effective for treating certain skin conditions in children.

Alopecia areata patients are more likely to have thyroid disorders than healthy individuals.

The document's conclusion cannot be determined.

Ashy dermatosis may be linked to atopy and thyroid disease and can be treated with topical steroids.

Baricitinib significantly improved hair regrowth and quality of life in severe alopecia areata patients.

Alopecia areata and atopic dermatitis have similar healthcare costs, but alopecia areata leads to more outpatient and long-term disability expenses.

INT effectively shows enzyme activity and protein groups in wool and hair follicles.

Tofacitinib helped improve symptoms and hair growth in a patient with Aicardi-Goutières syndrome.

IBD patients treated with TNF antagonists may develop autoimmune alopecia areata, with severe cases less likely to improve.

MT-DADMe-ImmA can selectively kill head and neck cancer cells without harming normal cells.

Baricitinib is effective as a treatment for severe hair loss.

JAK inhibitors improve hair growth in alopecia areata, especially in patchy types.

Baricitinib was effective and safe for severe hair loss treatment over 6 months.

Asynchronous telemedicine for acne treatment is effective and improves access and productivity.

Baricitinib, a drug for rheumatoid arthritis, atopic dermatitis, and alopecia areata, is generally safe with low risk of major side effects, even in patients with risk factors. It's also effective in promoting hair regrowth in alopecia areata patients.

Enhancing Tregs can protect against alopecia areata.